tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Ileus D045823 3 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Woodle ES et al. Tacrolimus therapy for refractory acute renal allograft rejection: a prospective multicenter trial. Tacrolimus Kidney Transplantation Rescue Study Group. 1996 Transplant. Proc. pmid:8962225
Scott-Douglas N et al. Treatment of acute renal transplant rejection with FK 506 in patients on cyclosporine after failure of standard antirejection therapy. 1996 Transplant. Proc. pmid:8962226
Kliem V et al. FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis. 1996 Transplant. Proc. pmid:8962227
Becker G et al. Tacrolimus (FK 506) therapy in simultaneous pancreas kidney transplantation. 1996 Transplant. Proc. pmid:8962228
Kiuchi T et al. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. 1996 Transplant. Proc. pmid:8962229
Guckelberger O et al. Does the choice of primary immunosuppression influence the prevalence of cardiovascular risk factors after liver transplantation? 1996 Transplant. Proc. pmid:8962230
Braun F et al. Clinical relevance of monitoring tacrolimus: comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus. 1996 Transplant. Proc. pmid:8962231
Wilczek HE et al. Renal transplant histopathologic changes during the first year in patients with tacrolimus (FK 506). 1996 Transplant. Proc. pmid:8962232
Yussim A et al. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation. 1996 Transplant. Proc. pmid:8962233
Golling M et al. Tacrolimus reduction improves glucose metabolism and insulin secretion after liver transplantation. 1996 Transplant. Proc. pmid:8962234
Platz KP et al. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients. 1996 Transplant. Proc. pmid:8962235
Mollison KW et al. Discovery of FK 506 analogues that are nontoxic to mouse pancreatic beta cells in vitro but show diabetogenic potential when administered to the rat. 1996 Transplant. Proc. pmid:8962236
Yokoyama I et al. Decreased Fas antigen expression of cultured hepatocytes with FK 506. 1996 Transplant. Proc. pmid:8962237
Mueller AR et al. Long-term follow-up in hepatitis C patients with respect to immunosuppression. 1996 Transplant. Proc. pmid:8962255
Jonas S et al. Posttransplant malignancy and newer immunosuppressive protocols after liver transplantation. 1996 Transplant. Proc. pmid:8962257
Kawasaki M et al. [Immunosuppression and the problems in partial liver transplantation]. 1995 Nihon Rinsho Meneki Gakkai Kaishi pmid:8963785
Teraoka S et al. [Present status and problems in clinical application of tacrolimus(FK506)]. 1995 Nihon Rinsho Meneki Gakkai Kaishi pmid:8963787
Guérette B et al. Increased interferon-gamma mRNA expression following alloincompatible myoblast transplantation is inhibited by FK506. 1996 Muscle Nerve pmid:8965835
Sharkey J et al. Tacrolimus (FK506) ameliorates skilled motor deficits produced by middle cerebral artery occlusion in rats. 1996 Stroke pmid:8969794
Hedayat S et al. Relationship of whole-blood FK506 concentrations to rejection and toxicity in liver and kidney transplants. 1996 J Biopharm Stat pmid:8969977
Taler SJ et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. 1996 Transplantation pmid:8970613
Hisanaga Y et al. Implication of nitric oxide synthase activity in the genesis of water immersion stress-induced gastric lesions in rats: the protective effects of FK506. 1996 Aliment. Pharmacol. Ther. pmid:8971291
Corey HE et al. Improved renal allograft survival in children treated with FK 506 (tacrolimus) rescue therapy. 1996 Pediatr. Nephrol. pmid:8971888
Morris RE Transplantation. Beware: shifting paradigms ahead. 1996 Dec 21-28 Lancet pmid:8973504
James DG A new immunosuppressant: tacrolimus. 1996 Postgrad Med J pmid:8977938
Blecher O et al. A novel plant peptidyl-prolyl-cis-trans-isomerase (PPIase): cDNA cloning, structural analysis, enzymatic activity and expression. 1996 Plant Mol. Biol. pmid:8980498
Odom A et al. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. 1997 Antimicrob. Agents Chemother. pmid:8980772
Nichterlein T et al. Effects of FK-506 on the course of murine salmonellosis. 1996 J Chemother pmid:8981186
Redmon JB et al. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. 1996 J. Clin. Invest. pmid:8981925
Sempuku T et al. Osteogenic potential of allogeneic rat marrow cells in porous hydroxyapatite ceramics: a histological study. 1996 J. Orthop. Res. pmid:8982133
High KP and Washburn RG Invasive aspergillosis in mice immunosuppressed with cyclosporin A, tacrolimus (FK506), or sirolimus (rapamycin). 1997 J. Infect. Dis. pmid:8985226
Yoshikai Y et al. Clonal expansion of superantigen-reactive T cells is resistant to FK506 in mice with AIDS. 1997 J. Virol. pmid:8985410
pmid:8986461
Shapiro R et al. Tacrolimus in pediatric renal transplantation. 1996 Transplantation pmid:8990356
Przepiorka D et al. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. 1996 Transplantation pmid:8990368
Rambusch EG and Manns MP [Therapy of autoimmune hepatitis]. 1996 Dtsch. Med. Wochenschr. pmid:8998922
Ericzon BG et al. Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus. 1997 Transplantation pmid:9000664
Kelly PA et al. Ciprofloxacin does not block the antiproliferative effect of tacrolimus. 1997 Transplantation pmid:9000686
Nair SC et al. Molecular cloning of human FKBP51 and comparisons of immunophilin interactions with Hsp90 and progesterone receptor. 1997 Mol. Cell. Biol. pmid:9001212
Pirenne J et al. Donor-specific unmodified bone marrow transfusion does not facilitate intestinal engraftment after bowel transplantation in a porcine model. 1997 Surgery pmid:9001555
Felldin M et al. Rescue therapy with tacrolimus (FK 506) in renal transplant recipients--a Scandinavian multicenter analysis. 1997 Transpl. Int. pmid:9002146
Becker G et al. Rescue therapy with tacrolimus in simultaneous pancreas/kidney transplantation. 1997 Transpl. Int. pmid:9002152
Matsui A et al. Apparently increased trough levels of tacrolimus caused by acute infantile diarrhea in two infants with biliary atresia after liver transplantation. 1996 Acta Paediatr Jpn pmid:9002314
DeCenzo MT et al. FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis and the stability of ligand complexes. 1996 Protein Eng. pmid:9005438
Noguchi N et al. Cyclic ADP-ribose binds to FK506-binding protein 12.6 to release Ca2+ from islet microsomes. 1997 J. Biol. Chem. pmid:9013543
Ishizuka T et al. Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells. 1997 Biochem. Biophys. Res. Commun. pmid:9016789
Richardson D et al. The successful conversion to Tacrolimus (FK506) of a renal transplant recipient with cyclosporin-induced haemolytic-uraemic syndrome. 1996 Nephrol. Dial. Transplant. pmid:9017633
Sano Y et al. Effect of a single injection of high-dose FK506 on lung transplantation in rats. 1996 Surg. Today pmid:9017963
Villalba L and Adams EM Update on therapy for refractory dermatomyositis and polymyositis. 1996 Curr Opin Rheumatol pmid:9018458
Jordan ML et al. Tacrolimus rescue therapy for renal allograft rejection--five-year experience. 1997 Transplantation pmid:9020321